Endothelial FAK as a therapeutic target in disease
| Autor: | Giovanni Infusino, Jeffrey R. Jacobson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Angiogenesis
Integrin Acute Lung Injury Respiratory System Agents Angiogenesis Inhibitors Lung injury Biochemistry Article Focal adhesion Arthritis Rheumatoid Neoplasms Medicine Animals Humans Diabetic Nephropathies Protein Kinase Inhibitors biology Neovascularization Pathologic business.industry Endothelial Cells Cardiovascular Agents Cell Biology Targeted drug delivery Cardiovascular Diseases Antirheumatic Agents Focal Adhesion Protein-Tyrosine Kinases Immunology Cardiovascular agent biology.protein Cancer research Signal transduction Cardiology and Cardiovascular Medicine business Tyrosine kinase Signal Transduction |
| Zdroj: | Microvascular research. 83(1) |
| ISSN: | 1095-9319 |
| Popis: | Focal adhesions (FA) are important mediators of endothelial cytoskeletal interactions with the extracellular matrix (ECM) via transmembrane receptors, integrins and integrin-associated intracellular proteins. This communication is essential for a variety of cell processes including EC barrier regulation and is mediated by the non-receptor protein tyrosine kinase, focal adhesion kinase (FAK). As FA mediate the basic response of EC to a variety of stimuli and FAK is essential to these responses, the idea of targeting EC FAK as a therapeutic strategy for an assortment of diseases is highly promising. In particular, inhibition of FAK could prove beneficial in a variety of cancers via effects on EC proliferation and angiogenesis, in acute lung injury (ALI) via the attenuation of lung vascular permeability, and in rheumatoid arthritis via reductions in synovial angiogenesis. In addition, there are potential therapeutic benefits of FAK inhibition in cardiovascular disease and diabetic nephropathy as well. Several drugs that target EC FAK are now in existence and include agents currently under investigation in preclinical models as well as drugs that are readily available such as the sphingolipid analog FTY720 and statins. As the role of EC FAK in the pathogenesis of a variety of diseases continues to be explored and new insights are revealed, drug targeting of FAK will continue to be an important area of investigation and may ultimately lead to highly novel and effective strategies to treat these diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect